Limited Submission Funding Opportunities – updated 11/02/18

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of $50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process
Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:
1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. Clinical and Translational Science Award (U54 Clinical Trial Optional)

   MGH LOI Deadline: 11/27/18
   NIH LOI Deadline: 12/25/18
   NIH Deadline: 1/25/19

   The purpose of this funding opportunity announcement (FOA) is to invite applications for the Clinical and Translational Science Award (CTSA) Program hubs, which support high quality collaborative translational science locally, regionally, and nationally; foster scientific and operational innovation to improve the efficiency and effectiveness of clinical translational research; and create, provide, and disseminate domain-specific translational science training and workforce development.
2. Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 – Clinical Trial Optional)
MGH LOI Deadline: 12/18/18
NIH LOI Deadline: 1/21/19
NIH Deadline: 2/21/19

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members. Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC. Multi-site clinical trials will not be considered responsive to this FOA.

3. Initiative for Maximizing Student Development (IMSD) (T32)
MGH LOI Deadline: 1/15/19
NIH Deadline: 2/22/19

The goal of the Initiative for Maximizing Student Development (IMSD) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-intensive institutions (i.e., those with a 3-year average of NIH Research Project Grant funding equal to or above $7.5 million total costs).

This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

4. Diabetes Research Centers (P30 Clinical Trial Optional)
MGH LOI Deadline: 4/08/19
NIH LOI Deadline: 5/20/19
NIH Deadline: 6/20/19

This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. Diabetes Research Centers support two primary research-related activities: Research Core services and a Pilot and Feasibility (P and F) program. All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity,
effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas. The NIDDK Diabetes Research Centers program in 2018 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in diabetes-related research. General information about the NIDDK Diabetes Research Centers program may be found at www.diabetescenters.org.